Intetumumab

Monotherapy with Intetumumab (10 mg/kg; i.p.; once weekly for 60 days) induces moderate tumor growth inhibition, with overall response rates of 33% and 17% in FaDu and A549 xenografts, respectively. This agent also significantly enhances the efficacy of fractionated radiotherapy, increasing the overall response rates to 89% and 67% in the two models, respectively. Meanwhile, it normalizes tumor vasculature, alleviates hypoxia, increases apoptosis, and causes no additional toxicity^[1].
Intetumumab (10 mg/kg; intraperitoneal injection; once weekly for 60 days) significantly reduces the lung metastasis rate of intravenously injected A549 cells, with the number of affected rats and the average number of metastatic lesions per lung decreased by 56% and 77%, respectively^[1].
Monotherapy with Intetumumab (10 mg/kg; intraperitoneal injection; once weekly for 60 days) reduces spontaneous lung metastasis of subcutaneously implanted A549 xenografts by 67% and enhances the anti-metastatic efficacy of radiotherapy^[1].
Intetumumab (10 mg/kg; intraperitoneal injection; single administration) does not significantly enhance the radiosensitivity of intestinal crypt stem cells in nude mice^[1].
Intetumumab enhances the efficacy of radiotherapy in a nude mouse xenograft model of human small cell lung cancer, delays tumor growth and reduces metastasis, without increasing the radiosensitivity of intestinal crypt stem cells^[2].
Intetumumab is well tolerated, showing no toxicity, histopathological changes, or adverse effects on physiological angiogenesis in cynomolgus monkeys following long-term administration^[2].
Intetumumab exerts anti-tumor and anti-angiogenic activities in nude mice bearing human melanoma xenografts^[2].
Intetumumab inhibits spontaneous metastasis of human breast cancer xenografts in nude mice^[2].